Great Point Partners’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-269,010
Closed -$11.9M 48
2021
Q3
$11.9M Buy
269,010
+19,010
+8% +$872K 2.78% 16
2021
Q2
$14.2M Sell
250,000
-132,085
-35% -$9.34M 2.98% 13
2021
Q1
$28.6M Sell
382,085
-72,332
-16% -$5.93M 5.91% 4
2020
Q4
$39.3M Sell
454,417
-1,512,271
-77% -$111M 6.39% 3
2020
Q3
$120M Sell
1,966,688
-135,680
-6% -$6.88M 10.81% 2
2020
Q2
$87.4M Buy
2,102,368
+277,889
+15% +$10.1M 6.99% 5
2020
Q1
$52.4M Buy
1,824,479
+1,028,422
+129% +$59.6M 5.47% 7
2019
Q4
$57.5M Buy
+796,057
New +$97.9M 5% 7
2018
Q1
Sell
-200,000
Closed -$32.9M 43
2017
Q4
$32.9M Buy
200,000
+90,500
+83% +$8.77M 5.62% 4
2017
Q3
$6.82M Sell
109,500
-134,300
-55% -$10.5M 1.33% 24
2017
Q2
$19.4M Sell
243,800
-58,009
-19% -$4.19M 3.48% 12
2017
Q1
$21.4M Sell
301,809
-83,874
-22% -$4.91M 4.26% 10
2016
Q4
$19.7M Buy
385,683
+120,790
+46% +$5.69M 4.05% 12
2016
Q3
$12.2M Sell
264,893
-65,107
-20% -$2.65M 3.11% 14
2016
Q2
$9.94M Buy
+330,000
New +$11M 2.85% 12

Other funds holding SAGE

Great Point Partners's SAGE Position: Q4 2021 in Review

Great Point Partners sold out of Sage Therapeutics (SAGE) in Q4 2021, closing a stake of 269,010 shares — an estimated $11.9M sold.

Great Point Partners first reported a position in SAGE in Q2 2016 and held it in 15 quarters. The position peaked at $120M in Q3 2020. 217 funds tracked by Wall St. Rank hold SAGE as of Q4 2021.

  • Great Point Partners reported no remaining Sage Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Great Point Partners sold 269,010 Sage Therapeutics shares in Q4 2021, an estimated $11.9M.
  • Great Point Partners first reported a position in Sage Therapeutics in Q2 2016 and held it in 15 quarters.
  • Great Point Partners's Sage Therapeutics position peaked at $120M in Q3 2020.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.